Crotedumab (REGN1193) (INN) is a humanized monoclonal antibody designed for the treatment of diabetes.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | GCGR |
| Clinical data | |
| Other names | REGN1193 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6518H10044N1732O2052S46 |
| Molar mass | 146976.88 g·mol−1 |
This drug was developed by Regeneron Pharmaceuticals but is no longer under development.[3]
References
edit- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Crotedumab, American Medical Association.
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- ^ Peterson SM, Hutchings CJ, Hu CF, Mathur M, Salameh JW, Axelrod F, Sato AK (April 2023). "Discovery and design of G protein-coupled receptor targeting antibodies". Expert Opinion on Drug Discovery. 18 (4): 417–428. doi:10.1080/17460441.2023.2193389. PMID 36992620.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |